Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year 2012 Financial Results

Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth
                Quarter and Fiscal Year 2012 Financial Results

PR Newswire

JERSEY CITY, N.J., Feb. 7, 2013

JERSEY CITY, N.J., Feb. 7, 2013 /PRNewswire/ --Optimer Pharmaceuticals, Inc.
(NASDAQ: OPTR) today announced it will report fourth quarter and fiscal year
2012 financial results after the NASDAQ Global Market closes on February 28.
The Company will host a conference call that day at 5:00 p.m. Eastern Time
(2:00 p.m. Pacific Time) to discuss the financial results and highlights for
thefourth quarter as well as provide a corporate update.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

The conference call may be accessed by dialing (877) 280-7280 for domestic
callers and +1 (678) 825-8232 for international callers. Please specify to the
operator that you would like to join "Optimer's Financial Results Call." The
conference call will be webcast live under the Investors section of Optimer's
website at www.optimerpharma.com, where it will be archived for 30 days
following the call.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc.is a global biopharmaceutical company focused on
developing and commercializing innovative hospital specialty products that
have a positive impact on society. Optimer developed DIFICID® (fidaxomicin)
tablets, anFDA-approved macrolide antibacterial drug for the treatment
ofClostridium difficile-associated diarrhea (CDAD) in adults 18 years of age
and older and is commercializing DIFICID in the US and Canada. Optimer also
received marketing authorization for fidaxomicin tablets in theEuropean
Unionwhere its partner,Astellas Pharma Europe, is commercializing
fidaxomicin under the trade name DIFICLIR™. The Company is exploring
marketing authorization in other parts of the world whereC. difficilehas
emerged as a serious health problem, includingAsia. Additional information
can be found at http://www.optimerpharma.com.

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
858-964-3418

Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005

SOURCE Optimer Pharmaceuticals, Inc.

Website: http://www.optimerpharma.com
 
Press spacebar to pause and continue. Press esc to stop.